Prostate cancer drug not prescribed because of cost

The Prostate Cancer Charity says that some men are being denied the drug docetaxel (Taxotere) simply on cost grounds.

Prostate cancer cells
Docetaxel was first licensed for the treatment of breast cancer, but was found to improveoverall survival, compared with the standard treatments, in patients with prostate cancer who had not responded to hormone therapy

NICE approved the use of docetaxel in June of this year, but a course of treatment costs approximately £7,000.

John Neate, chief executive of the Prostate Cancer Charity told the BBC: ‘It cannot be acceptable that men and their families who are already having to deal with the tough news of a prostate cancer diagnosis, have to wrestle with NHS bureaucracy at the same time.’

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in


Just published

Patient satisfaction screen

How a GP practice worked with patients to stop a torrent of complaints

A GP practice has seen complaints drop from 50-plus a day to just four in 10 months...

British Army soldiers marching

How the NHS Op COURAGE service can help support veterans

Armed forces veterans often have unique health needs. Clinical staff from London...

GP consultation

Continuity of care would save millions of GP appointments each year, new study finds

GP workload would be significantly reduced if continuity of care was prioritised...

Talking General Practice logo

Podcast: Visa sponsor shortage threatens GP workforce, locum GPs struggle to find work, record appointments

The GPonline team discusses the key news stories affecting general practice in our...

RCGP sign

RCGP condemns threat to retention funding as third of GPs consider quitting

Funding for GP retention risks being stripped away to cover other financial pressures...

Professor Dame Helen Stokes Lampard

Former RCGP chair joins NHS England board

Former RCGP chair Professor Dame Helen Stokes-Lampard has joined the NHS England...